Newcastle upon Tyne

QuantuMDx embarks on £11 million scale-up to mass manufacture its diagnostic Q-POCTM device and disposable test cassette

Retrieved on: 
Thursday, December 17, 2020
Medicine, Life sciences, Medical tests, Health, Biotechnology, Medical terminology, Point-of-care testing, Polymerase chain reaction, Molecular diagnostics, POC, Point of care

QuantuMDx Group Limited, a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today announced it is investing over 11 million to scale up production to mass manufacture its flagship diagnostic device, Q-POC and disposable test cassette.

Key Points: 
  • QuantuMDx Group Limited, a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today announced it is investing over 11 million to scale up production to mass manufacture its flagship diagnostic device, Q-POC and disposable test cassette.
  • QuantuMDx accelerated development, scale-up and manufacture of Q-POC - its rapid point-of-care testing system - earlier this year in response to the COVID-19 pandemic.
  • Q-POC is a portable, PCR device offering rapid, sample-to-answer, molecular diagnostic testing at the point of care, with results in approximately 30 minutes.
  • The Q-POC system comprises a sample collection kit, single-use test cassette and analyser.

QuantuMDx embarks on £11 million scale-up to mass manufacture its diagnostic Q-POCTM device and disposable test cassette

Retrieved on: 
Thursday, December 17, 2020
Medicine, Life sciences, Medical tests, Health, Biotechnology, Medical terminology, Point-of-care testing, Polymerase chain reaction, Molecular diagnostics, POC, Point of care

QuantuMDx Group Limited, a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today announced it is investing over 11 million to scale up production to mass manufacture its flagship diagnostic device, Q-POC and disposable test cassette.

Key Points: 
  • QuantuMDx Group Limited, a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today announced it is investing over 11 million to scale up production to mass manufacture its flagship diagnostic device, Q-POC and disposable test cassette.
  • QuantuMDx accelerated development, scale-up and manufacture of Q-POC - its rapid point-of-care testing system - earlier this year in response to the COVID-19 pandemic.
  • Q-POC is a portable, PCR device offering rapid, sample-to-answer, molecular diagnostic testing at the point of care, with results in approximately 30 minutes.
  • The Q-POC system comprises a sample collection kit, single-use test cassette and analyser.

QuantuMDx Launches Rapid, Sensitive SARS-CoV-2 Test

Retrieved on: 
Friday, May 1, 2020
Branches of biology, Molecular biology, Biology, Natural sciences, Laboratory techniques, Polymerase chain reaction, Biotechnology, Amplifiers, Reverse transcription polymerase chain reaction, Severe acute respiratory syndrome-related coronavirus, Reverse transcriptase

In addition, QuantuMDx has rigorously stress tested its supply chains and is confident in its ability to supply significant volumes of tests worldwide.

Key Points: 
  • In addition, QuantuMDx has rigorously stress tested its supply chains and is confident in its ability to supply significant volumes of tests worldwide.
  • QuantuMDxs SARS-CoV-2 assay is a real-time reverse transcriptase rtRT-PCR test that has been developed using advanced bioinformatics to maximise performance.
  • In response to the shortage of extraction kits in the current market, QuantuMDx is also validating the use of the test without the need for RNA extraction, running the RT-PCR test direct from swabs.
  • In addition to developing a SARS-CoV-2 test for laboratories, QuantuMDx continues preparations for scale- up and manufacture of its Q-POC rapid point-of-care testing device.

QuantuMDx and Ontera collaborate to advance sepsis diagnosis

Retrieved on: 
Tuesday, December 10, 2019
Medical specialties, Medicine, Clinical medicine, Intensive care medicine, Medical emergencies, Infectious diseases, Neonatology, Sepsis, Septic shock, Bacteremia, Urinary tract infection, Infection

QuantuMDx Group Limited and Ontera, Inc have announced a collaboration to create a next-generation solution for blood stream infection and drug resistance detection.

Key Points: 
  • QuantuMDx Group Limited and Ontera, Inc have announced a collaboration to create a next-generation solution for blood stream infection and drug resistance detection.
  • Sepsis affects more than 30 million people worldwide every year leading to an estimated 6 million deaths.
  • If its not recognized early and managed promptly with targeted antibiotics, sepsis can lead to septic shock, multiple organ failure and death.
  • By not only identifying sepsis but also resistance to most common antibiotics in less than 30 minutes, we will transform the sepsis landscape and impact lives, says Murielle Thinard McLane, CEO of Ontera.

Former Hearst UK Executive Joins Publisher A.I. Platform, Ezoic

Retrieved on: 
Thursday, September 6, 2018
World Wide Web, Geography of England, Hearst Communications, William Randolph Hearst, Google, North East England, Newcastle upon Tyne

LONDON, Sept. 5, 2018 /PRNewswire/ --Google Certified Publishing Partner, Ezoic , appoints former Hearst UK Chief Digital Officer, Paul Cassar, as new Vice President of Strategic Partnerships.

Key Points: 
  • LONDON, Sept. 5, 2018 /PRNewswire/ --Google Certified Publishing Partner, Ezoic , appoints former Hearst UK Chief Digital Officer, Paul Cassar, as new Vice President of Strategic Partnerships.
  • "At Hearst UK, I had the opportunity to get to know Ezoic.
  • Most of my career in digital media and publishing has been focused on user engagement, so joining Ezoic feels like natural fit for me.
  • Ezoic is a Google Certified Publishing Partner located in Carlsbad, California, USA with European teams at offices in Newcastle, UK and Covent Garden, London, UK.